Related Experiment Video
Updated: Sep 6, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease
Andrew McGarry1, Peggy Auinger1, Karl D Kieburtz1
1Department of Neurology (AM), Cooper University Healthcare at Rowan University, Camden, NJ; Center for Health and Technology (PA), University of Rochester, NY; Department of Neurology (KDK), University of Rochester, NY; University of Rochester (A-LB), NY; and Department of Neurology (SMH, HDR), Harvard Medical School, Boston, MA.
Background And Objectives:
Suicidality is a common concern in the routine care of persons with Huntington disease (HD) and for the many participants in HD clinical trials. In a previous analysis, we identified baseline and time-dependent factors associated with suicidal ideation and attempts from 2CARE, a large, randomized, double-blind clinical trial.
Methods:
The present analysis extends our prior methodology to 2 other large interventional HD clinical trials, CARE-HD and CREST-E.
Results:
We observed relationships across studies between suicidality events and prior suicidal ideation at baseline, antidepressant/anxiolytic use, chorea, increasing age, and several domains in the Unified Huntington Disease Rating Scale (UHDRS) Behavioral Assessment (depressed mood, low self-esteem, aggression, and active suicidality).
Discussion:
These data may form the basis for a subscale of demographic and UHDRS items with the potential for prospectively identifying suicidality risk in HD clinics and clinical trials.
Trial Registration Information:
2CARE and CREST are registered at clinicaltrials.gov. 2CARE NCT00608881, registered February 6, 2008; first enrollment March 2008. CREST-E NCT00712426, registered July 10, 2008; first enrollment September 2009. CARE-HD, not registered; first enrollment July 1997.
More Related Videos
10:52Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
Published on: December 10, 2021
08:27Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
Published on: March 11, 2020
Related Concept Videos
Hazard Ratio
For example, in a clinical trial...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Clinical Trials: Overview
Antidepressant Drugs: MAOIs and Other Agents
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Clinical Trials
There are four phases in a clinical trial. A phase one...